Service decision and evidence guide

Australian sponsor handoff: manufacturer evidence, supplier updates and incidents

Use this guide to compare ongoing manufacturer-to-sponsor evidence access, change communication and incident-handling deliverables. It does not establish sponsor eligibility, the device route, ARTG coverage or UDI applicability. Resolve those questions separately before presenting this handoff plan as a complete market-entry service. The acquired TGA guidance describes an ongoing sponsor role linking the manufacturer, Australian supply chain and regulator. An appointment needs workable evidence access, change/alert communication and incident handling. ARTG inclusion and Australian UDI preparation are different tasks; a UDI record does not establish ARTG coverage.

Evidence retrieved 2026-10-06. Source versions and topic-specific limits are listed below.

Sourced criteria · Australia

What changes the service scope?

Decision or taskWhat the source describesWhat to prepare
How does the sponsor reach the manufacturer?TGA describes sponsors as the link exchanging information between manufacturers and the regulator. [1]Agree covered products/entities, responsible people, document access and escalation before the appointment.
Who supports decisions and corrective actions?The guidance describes sponsor cooperation with the manufacturer and TGA concerning devices supplied or intended for supply. [2]Allocate investigation, document retrieval, decision and communication responsibilities without treating the appointment as a transfer of all manufacturer work.
How do Australian suppliers receive current information?The guidance addresses current information to suppliers/distributors, including ARTG status changes and safety/recall alerts. [3]Keep the supplied portfolio, ARTG evidence and distribution contacts mapped; distinguish UDI data work from authorization evidence.
How are reportable incidents handled?The guidance describes sponsor reporting of adverse or near-adverse events through IRIS and the eBusiness Portal. [4]Agree intake, assessment, manufacturer cooperation and authorized reporting ownership; review applicable thresholds and timeframes separately.

The actual device route, ARTG evidence, sponsor eligibility, conditions of inclusion, UDI applicability and reporting timeframes remain incomplete. This is dated post-market guidance, not a complete market-entry determination or proof of provider availability.

Australian sponsor evidence and incident handoff

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. How does the sponsor reach the manufacturer?

    Agree covered products/entities, responsible people, document access and escalation before the appointment.

    Useful evidence: Manufacturer/sponsor role matrix, portfolio and evidence-access commitments.

    Reported context: [1]

  2. Who supports decisions and corrective actions?

    Allocate investigation, document retrieval, decision and communication responsibilities without treating the appointment as a transfer of all manufacturer work.

    Useful evidence: Investigation/change-control procedure and named escalation contacts.

    Reported context: [2]

  3. How do Australian suppliers receive current information?

    Keep the supplied portfolio, ARTG evidence and distribution contacts mapped; distinguish UDI data work from authorization evidence.

    Useful evidence: Portfolio-to-ARTG evidence map, supply-chain contacts and change/alert workflow.

    Reported context: [3]

  4. How are reportable incidents handled?

    Agree intake, assessment, manufacturer cooperation and authorized reporting ownership; review applicable thresholds and timeframes separately.

    Useful evidence: Incident intake/assessment workflow, authorized reporting role and record access.

    Reported context: [4]

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

Therapeutic Goods Administration — published reference ↗

2026-03-12 official guidance update; rendered article capture · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D09 · snapshot 7a3a49757f57c01f7f1e2d26c588fdceac7f22985ccaad995efd2fef364ca236

  • [1] HTML p [51] · record 04bd3cc1c3ac4e194b2310410e5c68cb25b1dbcb25ab91f59427b55fe475c55d
  • [2] HTML p [52] · record 9c157b8dc117dd0f255ec3d44f8f7d16f60cccad6402c065b093490d968a85de
  • [3] HTML p [53] · record 4886a0f993916f05fcd355b4ce31491a0bcd3c5e6bdfafa122ae8ffa813237fa
  • [4] HTML p [125] · record d03025dea14418e16820a76dca55b157e4e548fe55fd65eabdcb13c94c4d246a

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare Find AU TGA Sponsors | Compare Providers & Get Quotes